| Literature DB >> 29403355 |
Xin-Yuan Cao1,2, Xu Hua2, Jian-Wei Xiong2, Wen-Ting Zhu3, Jun Zhang3, Ling Chen1,2.
Abstract
Triclosan (TCS), a broad-spectrum antimicrobial agent, is widely used in clinical settings and various personal care products. The aim of this study was to evaluate the influence of TCS on reproductive endocrine and function. Here, we show that the exposure of adult female mice to 10 or 100 mg/kg/day TCS caused prolongation of diestrus, and decreases in antral follicles and corpora lutea within 2 weeks. TCS mice showed decreases in the levels of serum luteinizing hormone (LH), follicle-stimulating hormone (FSH) and progesterone, and gonadotrophin-releasing hormone (GnRH) mRNA with the lack of LH surge and elevation of prolactin (PRL). TCS mice had lower kisspeptin immunoreactivity and kiss1 mRNA in anteroventral periventricular nucleus (AVPV) and arcuate nucleus (ARC). Moreover, the estrogen (E2)-enhanced AVPV-kisspeptin expression was reduced in TCS mice. In addition, the serum thyroid hormones (triiodothyronine (T3) and thyroxine (T4)) in TCS mice were reduced with increases in levels of thyroid stimulating hormone (TSH) and thyroid releasing hormone (TRH). In TCS mice, the treatment with Levothyroxine (L-T4) corrected the increases in PRL, TSH and TRH; the administration of L-T4 or type-2 dopamine receptors agonist quinpirole inhibiting PRL release could rescue the decline of kisspeptin expression in AVPV and ARC; the treatment with L-T4, quinpirole or the GPR45 agonist kisspeptin-10 recovered the levels of serum LH and FSH and progesterone, and GnRH mRNA. Furthermore, TCS mice treated with L-T4 or quinpirole resumed regular estrous cycling, follicular development and ovulation. Together, these results indicate that exposing adult female mice to TCS (≥10 mg/kg) reduces thyroid hormones causing hyperprolactinemia that then suppresses hypothalamic kisspeptin expression, leading to deficits in reproductive endocrine and function.Entities:
Keywords: estrous cycle; kisspeptin; prolactin; thyroid hormones; triclosan
Year: 2018 PMID: 29403355 PMCID: PMC5780345 DOI: 10.3389/fnmol.2018.00006
Source DB: PubMed Journal: Front Mol Neurosci ISSN: 1662-5099 Impact factor: 5.639
Figure 1Time chart of experimental procedure. Hollow arrow indicates experimental time (day). “+” indicates the time of drugs administration and examination.
Figure 2Triclosan (TCS) causes prolongation of diestrus. (A) Body weights (g) of mice. (B) Representative estrous cycles before and after TCS-exposure for 50 days. Connected dots indicate the time of diestrus (D), proestrus (P) or estrus (E), respectively. *: persistent diestrus; ↑: loss of proestrus. (C) Bar graph shows the mean time (day) of one estrous cycle within TCS-exposure. **P < 0.01 vs. control mice (one-way ANOVA). (D) Bars represent the mean length (day) of diestrus (D), proestrus (P), or estrus (E), respectively, per estrous cycle. **P < 0.01 vs. control mice (one-way ANOVA).
Figure 3TCS affects follicle development and ovulation. (A) Representative images of ovaries stained with hematoxylin and eosin (HE) in control mice and TCS mice. #: antral follicles; ↑: atretic follicles; *: corpora luteum. Scale bars = 200 μm. (A-i,A-ii) Bar graphs represent the mean number of antral follicles and corpora luteum at diestrus, respectively. *P < 0.05 vs. control mice (one-way ANOVA).
Figure 4TCS suppresses luteinizing hormone (LH)-surge and kisspeptin expression. (A) Each point represents mean levels of LH that are normalized by the LH level at 1600. **P < 0.01 vs. control mice (one-way ANOVA). (B) Representative picture of kisspeptin immune-staining in anteroventral periventricularnucleus (AVPV) of proestrus control mice and TCS mice. Black arrows indicate AVPV-kisspeptin+ cells. Scale bars = 100 μm. (C,D) Bar graphs indicate the levels of AVPV-kiss1 mRNA in proestrus mice or E2-treated OVX mice. *P < 0.05 and **P < 0.01 vs. control mice; ##P < 0.01 vs. OVX 10-TCS mice; $$P < 0.01 vs. E2-treated ovariectomized (OVX) control mice (two-way ANOVA). (E) Representative picture of kisspeptin immune-staining in arcuate nucleus (ARC) of diestrus control mice and TCS mice. Scale bars = 100 μm. (F) Bars indicate the levels of ARC-kiss1 mRNA in diestrus control mice and TCS mice. *P < 0.05 vs. control mice (one-way ANOVA).
Figure 5TCS-reduced kisspeptin causes persistent diestrus and ovary dysfunction. (A,B) Bar graphs indicate the levels of AVPV-kiss1 mRNA and ARC-kiss1 mRNA in 10-TCS mice treated with Levothyroxine (L-T4) or quinpirole (Quin). *P < 0.05 vs. control mice; #P < 0.05 vs. 10-TCS mice (two-way ANOVA). Bar graphs represent the length (day) of diestrus (C), the number of antral follicles (D) and corpora luteum at diestrus (E) in 10-TCS mice treated with L-T4 or Quin. *P < 0.05 vs. control mice; #P < 0.05 vs. 10-TCS mice; **P< 0.01 vs. control mice; ##P < 0.01 vs. 10-TCS mice (two-way ANOVA).
Prolactin (PRL) and hypothalamic-pituitary-gonad and -thyroid hormones.
| Control | 1-TCS | 10-TCS | 100-TCS | |
|---|---|---|---|---|
| FSH (IU/L) | 1.80 ± 0.42 | 1.79 ± 0.60 | 1.46 ± 0.25* | 1.25 ± 0.49* |
| LH (IU/L) | 1.08 ± 0.31 | 0.94 ± 0.38 | 0.80 ± 0.17* | 0.71 ± 0.26** |
| E2 (pg/ml) | 20.01 ± 3.88 | 17.29 ± 2.19 | 16.57 ± 4.40 | 15.74 ± 5.15 |
| P4 (ng/ml) | 4.27 ± 0.86 | 3.87 ± 0.66 | 3.52 ± 0.45* | 3.18 ± 0.89* |
| PRL (ng/L) | 54.95 ± 9.46 | 55.83 ± 7.25 | 61.34 ± 8.76* | 62.04 ± 10.00* |
| 1.00 ± 0.13 | 0.95 ± 0.18 | 0.71 ± 0.21** | 0.65 ± 0.19** | |
| T4 (ng/ml) | 54.63 ± 13.64 | 53.74 ± 12.72 | 44.65 ± 11.79* | 26.19 ± 20.65** |
| T3 (ng/ml) | 1.67 ± 0.35 | 1.62 ± 0.30 | 1.40 ± 0.36* | 1.23 ± 0.55** |
| TSH (μIU/ml) | 1.26 ± 0.23 | 1.21 ± 0.28 | 1.48 ± 0.43* | 1.49 ± 0.35* |
| TRH (ng/L) | 0.98 ± 0.30 | 1.05 ± 0.39 | 1.29 ± 0.47* | 1.33 ± 0.50* |
*P < 0.05, **P < 0.01 vs. control.
Hypothalamic-pituitary trophic hormones and PRL.
| Control | 10-TCS | 10-TCS/L-T4 | 10-TCS/Quin | 10-TCS/Kp-10 | |
|---|---|---|---|---|---|
| FSH (IU/L) | 1.80 ± 0.42 | 1.46 ± 0.25* | 1.69 ± 0.21# | 1.73 ± 0.29# | 1.68 ± 0.19# |
| LH (IU/L) | 1.08 ± 0.31 | 0.80 ± 0.17* | 0.95 ± 0.13# | 1.05 ± 0.19## | 0.96 ± 0.16# |
| 1.00 ± 0.13 | 0.71 ± 0.21** | 0.87 ± 0.05# | 0.95 ± 0.06## | 0.90 ± 0.06# | |
| PRL (ng/L) | 54.95 ± 9.46 | 61.34 ± 8.76* | 56.47 ± 6.03# | 54.55 ± 6.37## | 59.25 ± 12.17 |
| TSH (μIU/ml) | 1.26 ± 0.23 | 1.48 ± 0.43* | 1.26 ± 0.21# | 1.40 ± 0.52 | 1.37 ± 0.39 |
| TRH (ng/L) | 0.98 ± 0.30 | 1.29 ± 0.47* | 1.02 ± 0.23# | 1.25 ± 0.29 | 1.30 ± 0.41 |
*P < 0.05, **P < 0.01 vs. control; .